The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | BTK degraders in the treatment of CLL
Catherine Coombs, MD, UC Irvine Health, Orange, CA, comments on the use of BTK degraders as a potentially more effective treatment strategy than BTK inhibitors in chronic lymphocytic leukemia (CLL). Despite being in the early stages of development with limited trial follow-ups, Dr Coombs is optimistic about this novel mechanism, noting its efficacy in patients who are resistant to pirtobrutinib. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
